Integrating coronary atherosclerosis with physiologic features for optimized risk stratification

Ended Project Grant Awarded Last action

Award ID
R01HL146144
Recipient
Awarding agency
Obligated
$7,355,333

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Originally
Funding
  • $6,177,258.00 Federal
  • $1,178,075.00 Non-federal
Place of performance
Massachusetts, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Coronary artery disease (CAD) is the principal basis of morbidity and mortality worldwide, and more than half of individuals experiencing acute myocardial infarction (AMI) have no premonitory symptoms. Coronary CT angiography is a non-invasive technique that permits low-dose volumetric imaging of the coronary arteries in a single heartbeat. CT is accurate compared to invasive angiography, and angiographic severity of coronary artery disease (CAD) by CT enables prognostication of ACS and death. Beyond luminal narrowing, CT enables quantitative evaluation of an array of atherosclerotic plaque characteristics (apcs). Further, application of computational fluid dynamics to CT enables determination of an array of coronary physiologic characteristics (cpcs), such as fractional flow reserve, endothelial wall shear stress, vorticity, particle resident time, axial plaque stress and plaque structural stress. To date, among cpcs, only ESS-in studies performed by our group-has been evaluated for its influence on future ACS risk, and was done so in select post-ACS populations of patients undergoing invasive imaging. Yet, the remainder of cpcs has not been evaluated for their prognostic importance to ACS risk, and none has been assessed in a stable population without known CAD. Further, combining cpcs with apcs for improved risk stratification of future ACS remains virtually unexplored. The overall hypothesis of this proposal is that integration of coronary atherosclerosis with coronary physiologic features will improve identification of stable individuals who will subsequently experience ACS beyond any coronary feature alone. We propose 3 aims: aim 1. To characterize cpcs associated with future ACS. Hypothesis: cpcs within arteries and exerted on plaques that will be implicated in future ACS will differ from cpcs within arteries and exerted on plaques that will not be implicated in future ACS. Aim 2. To integrate cpcs with apcs for enhanced identification of stable individuals who will experience future ACS. Hypothesis: a multi-dimensional framework that integrates the entirety of coronary atherosclerosis and pathophysiologic features will be superior to frameworks that do not integrate coronary atherosclerosis and pathophysiologic features for identification of individuals who will experience future ACS. Aim 3. To validate the clinical tool developed in aim 2 in stable individuals with suspected CAD. Hypothesis: applied to a general population of stable individuals with suspected but without known CAD enrolled in the randomized controlled scot-heart trial, a clinical tool that integrates coronary atherosclerosis and coronary pathophysiologic features will be effective for prediction of ACS. If successful, the work in this proposal will provide the rationale for a novel diagnostic and prognostic paradigm that can be readily applied in clinical care of patients with suspected CAD. Further, this work will offer unique insights into the pathophysiology of CAD.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $57,159 $0
Amendment $643,051 $0
Amendment $643,051 $0
Amendment $639,123 $0
Amendment $639,123 $0
Amendment $639,123 $0
Amendment $17,665 $0
Amendment $0 $0
Amendment $0 $0
Amendment $17,665 $17,665
Amendment $17,665 $0
Amendment $0 $0
Amendment $54,283 $0
Amendment $54,283 $54,283
Amendment $54,283 $0
Amendment $488,530 $0
Amendment $488,530 $488,530
Amendment $488,530 $0
Amendment $0 $0
Amendment $0 $0
Amendment $617,597 $0
Original award $617,597 $617,597
Show all 23

Subawards

Subrecipient Amount Awarded
The University Of Edinburgh Dr. Newby will assist in the evaluation of the CT database comprised of detailed CT-based measures. Dr Newby will also provide insights into the study and… $50,760
Northeastern University During Years 1-3, Dr. Coskun will work on Specific Aims 1 and 2 to develop computational fluid dynamics (CFD) model to determine physiologic plaque… $356,772
Northeast Georgia Medical Center, Inc. Dr. Samady is the Director of the Georgia Cardiovascular Imaging and Biochemical Core laboratory as well as adjunct professor of Medicine at Emory University… $189,952
Cleerly, Inc. Two radiologic technologists from Cleerly will serve as co-investigators. The technologists will manage all incoming and outgoing CTA data and conduct quality… $579,192

Quick answers

Who received award R01HL146144?

R01HL146144 was awarded to Brigham & Womens Hospital Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on March 4, 2021.

How much is award R01HL146144 worth?

$7,355,333 has been obligated on R01HL146144: $6,177,258 in federal funding and $1,178,075 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login